- In May 2024, Oxford Nanopore Technologies launched a new Pharmacogenomics (PGx) Beta Program aimed at advancing personalized medicine by integrating Twist Bioscience’s next-generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform
- In February 2024, Nicklaus Children's Hospital in South Florida implemented the next-generation pharmacogenomics technology, specifically the Applied Biosystems PharmacoScan Solution and GeneTitan MC Fast Scan Instrument, to create personalized treatment plans for patients, thereby minimizing complications from drug interactions and side effects
- In July 2023, Illumina Inc. formed a partnership with Pillar Biosciences Inc. to incorporate Pillar's oncology assays into Illumina's global oncology product offerings. This collaboration will merge various next-generation sequencing solutions, resulting in an exceptional array of complementary tools. The advancements in sequencing methodologies are expected to enhance the efficiency, accuracy, and cost-effectiveness of oncology testing, ultimately aiming to expand patient access to personalized cancer treatment alternatives
- In April 2023, Integrated DNA Technologies, Inc. completed the acquisition of Archer NGS research assays from Invitae Corporation, enhancing the xGen NGS product lineup and accelerating oncology research, particularly in the identification of new cancer fusions. This integration into IDT's extensive xGen NGS portfolio provides researchers with streamlined solutions for uncovering critical biomarkers, especially those related to significant cancer fusions
- In January 2023, QIAGEN announced the acquisition of Verogen, a company specializing in next-generation sequencing (NGS) technologies for human identification (HID) and forensic application
Frequently Asked Questions
The market is segmented based on Segmentation, By Product and Service (Kits and Reagents and Services), Disease Area (Cancer, Cardiovascular, Neurological Diseases, and Other Disease Areas), Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, and Mass Spectrometry), Application (Drug Discovery, Neurology, Oncology, Pain Management, and Others), End-Users (Hospitals, Research Organisation, and Others) – Industry Trends and Forecast to 2031
.
The Global Pharmacogenomics Market size was valued at USD 8.69 USD Billion in 2023.
The Global Pharmacogenomics Market is projected to grow at a CAGR of 10.8% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
